Published in Clin Exp Rheumatol on August 06, 1991
Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis (2010) 1.01
Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J (2007) 0.83
Serum amyloid A circulating levels and disease activity in patients with juvenile idiopathic arthritis. Yonsei Med J (2012) 0.80
[Clinical and serological findings of giant-cell arteritis]. Z Rheumatol (2009) 0.76
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Systemic capillary leak syndrome: report on 13 patients with special focus on course and treatment. Am J Med (1997) 3.01
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem (2000) 2.18
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem (1997) 2.18
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol (1999) 2.05
Pulmonary involvement in polymyositis and in dermatomyositis. J Rheumatol (1998) 2.00
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem (2000) 1.95
Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) (2013) 1.90
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 1.88
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest (1995) 1.88
Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr (1998) 1.74
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest (1995) 1.74
Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum (2002) 1.67
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem (1999) 1.66
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation (2000) 1.65
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep (2001) 1.64
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun (2004) 1.61
Cannabis arteritis revisited--ten new case reports. Angiology (2001) 1.58
Transcriptional control of adipogenesis. Curr Opin Cell Biol (1998) 1.52
Embolization of two bleeding aneurysms with platinum coils in a patient with polyarteritis nodosa. J Rheumatol (1993) 1.51
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes (2001) 1.50
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest (2001) 1.47
Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis (1987) 1.47
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem (1990) 1.46
Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol (2001) 1.46
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans (2006) 1.44
An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem (1990) 1.43
Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation (1996) 1.43
Lipid traffic between high density lipoproteins and Plasmodium falciparum-infected red blood cells. J Cell Biol (1991) 1.43
Hypothenar hammer syndrome followed by systemic sclerosis. J Rheumatol (2000) 1.42
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem (1989) 1.41
[Dermatopolymyositis and chronic lymphoid leukemia. Apropos of 2 cases]. Rev Med Interne (1993) 1.39
Magnetic resonance imaging in focal myositis. J Rheumatol (1998) 1.39
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science (1996) 1.39
[Testicular localization of systemic diseases]. Presse Med (1995) 1.39
[Peripheral T-lymphocyte subpopulations in primary and alcoholic dilated cardiomyopathy]. Ann Med Interne (Paris) (1985) 1.39
The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem (1998) 1.38
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 1.38
Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res (2005) 1.37
Fasting during Ramadan induces a marked increase in high-density lipoprotein cholesterol and decrease in low-density lipoprotein cholesterol. Ann Nutr Metab (1997) 1.37
Long-term follow-up of neurosarcoidosis. Neurology (2001) 1.36
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol (1995) 1.35
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun (1987) 1.30
Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem (1990) 1.30
Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene (1994) 1.26
Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) (1999) 1.26
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol (2000) 1.26
[Chorea and systemic lupus erythematosus with circulating anticoagulant. 3 cases]. Rev Neurol (Paris) (1985) 1.25
Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum (2011) 1.24
Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology (2000) 1.24
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis (1996) 1.22
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest (1996) 1.22
Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem (2000) 1.21
[Study of beta-D-galactosidase of mycobacteria. (Preliminary note)]. Ann Inst Pasteur (Paris) (1966) 1.20
Immunological profile in primary Sjögren syndrome: clinical significance, prognosis and long-term evolution to other auto-immune disease. Autoimmun Rev (2010) 1.19
Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest (1998) 1.18
Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. J Biol Chem (1997) 1.18
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem (2001) 1.17
Acute myelopathies: Clinical, laboratory and outcome profiles in 79 cases. Brain (2001) 1.17
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation (1996) 1.17
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem (1994) 1.17
Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum (2000) 1.17
Influence of pulmonary dust load on the development of experimental infection by Mycobacterium kansasii. Nature (1967) 1.14
The epitopes of apolipoprotein A-I define distinct structural domains including a mobile middle region. J Biol Chem (1991) 1.12
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation (2001) 1.12
Subclinical pulmonary involvement in collagen-vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis (1986) 1.11
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res (1992) 1.10
POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia (1997) 1.09
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol (1994) 1.08
Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med (2000) 1.07
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci (1999) 1.07